Breaking Finance News

Peel Hunt disclosed Oxford BioMedica PLC (LON:OXB), hiking its price target to 13.00GBX earlier today

Having a price of 8.76GBX, Oxford BioMedica PLC (LON:OXB) traded 5.26% higher on the day. With the last stock price up 26.61% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. OXB has recorded a 50-day average of 8.87GBX and a two hundred day average of 6.63GBX. Trade Volume was down over the average, with 2,699,095 shares of OXB changing hands under the typical 13,806,400

Reporting a potential upside of 0.48%, Peel Hunt upped the price target of Oxford BioMedica PLC (LON:OXB) to 13.00GBX

On 08/31/2017, N+1 Singer released a statement about Oxford BioMedica PLC (LON:OXB) upped the target price from 8.70GBX to 10.20GBX that suggested an upside of 0.01%.

Recent Performance Chart

Oxford BioMedica PLC (LON:OXB)

Oxford BioMedica PLC has with a one year low of 2.98GBX and a one year high of 11.25GBX and has a market capitalization of 0 GBX.

General Company Details For Oxford BioMedica PLC (LON:OXB)

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.